AZN (AstraZeneca) Cash-to-Debt : 0.21 (As of Jun. 2024)

View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AstraZeneca's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.21.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AstraZeneca couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for AstraZeneca's Cash-to-Debt or its related term are showing as below:

AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 0.25 Max: 0.65
Current: 0.21

During the past 13 years, AstraZeneca's highest Cash to Debt Ratio was 0.65. The lowest was 0.17. And the median was 0.25.

AZN's Cash-to-Debt is ranked worse than
75.42% of 1017 companies
in the Drug Manufacturers industry
Industry Median: 0.97 vs AZN: 0.21

AstraZeneca Cash-to-Debt Historical Data

The historical data trend for AstraZeneca's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AstraZeneca Cash-to-Debt Chart

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.34

0.39

0.21

AstraZeneca Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															0.20	0.18	0.21	0.23	0.21

Competitive Comparison of AstraZeneca's Cash-to-Debt

For the Drug Manufacturers - General subindustry, AstraZeneca's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cash-to-Debt falls into.

AstraZeneca Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AstraZeneca's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5860	/	(5400	+	23222)
	=	0.20

AstraZeneca's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7076	/	(5359	+	28174)
	=	0.21

AstraZeneca (NAS:AZN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AstraZeneca Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZN1:Mexico AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.